Neuralink raises $650M to help expand patient access
Elon Musk's Neuralink closed a $650 million funding in a Series E round, the company said Monday.
The company said it plans to use the funds to expand patient access and 'innovate future devices that deepen the connection between biological and artificial intelligence.'
Neuralink also announced that its brain implant has entered clinical trials in three countries, and that five people with severe paralysis are now using the implant to control digital and physical devices.
Neuralink's brain computer interface consists of a chip that is surgically implanted in the skull, as well as electrodes that connect to the brain's cerebral cortex. It's designed to allow people to control a computer or mobile device.
The latest fundraise included investors ARK Invest, Founders Fund, G42, Lightspeed, Sequoia Capital and others. Neuralink previously raised $280 million in a Series D round in 2023.
Last year, Noland Arbaugh became the first person to receive the implant, which allowed him to move a cursor on a screen and play video games.
Since then, Neuralink has sought additional applications. The company said last month it received the Food and Drug Administration's breakthrough designation to help restore communication for individuals with severe speech impairment. In Monday's announcement, Neuralink also said it had received breakthrough designation for vision restoration programs.
The FDA determines breakthrough devices based on their potential for more effective treatment of life-threatening or irreversibly debilitating conditions. The designation gives manufacturers the opportunity to meet with FDA experts and have their submissions prioritized for review.
Neuralink also said it has started clinical trials at the Barrow Neurological Institute in Phoenix, The Miami Project to Cure Paralysis at the University of Miami, the Cleveland Clinic Abu Dhabi and the University Health Network in Toronto.
Recommended Reading
Elon Musk's brain implant company raises $280M to fund clinical trials
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
3 minutes ago
- Newsweek
Gen Z and Millennials Have Differing Views on Ozempic
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity. While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more. But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more. Why It Matters GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years. Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes. However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons. Ozempic is medicine for adults with type 2 diabetes. Ozempic is medicine for adults with type 2 diabetes. Steve Christo - Corbis/Corbis via Getty Images What To Know The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity. At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more. Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer. "Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek. "Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not." Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported. There was also a difference in how the generations viewed their use of the drugs. While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent. What People Are Saying Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations." Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies." What Happens Next The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.
CBS News
3 minutes ago
- CBS News
Wegmans recalls some cheese products due to potential listeria contamination
Wegmans is recalling its brand of medium camembert cheese and products that contain it due to potential listeria contamination, which can lead to serious illness. In an alert Wednesday, the U.S. Food and Drug Administration said the affected items, which were sold between July 1 and Aug. 12, include: The affected products were sold at Wegmans in the following locations: So far, no illnesses have been reported to Wegmans or its supplier, but officials say customers should not consume the products and can return them for a full refund. Listeria infections are caused by eating food contaminated with the bacteria called Listeria monocytogenes. In healthy individuals, short-term symptoms may include high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea. But for young children, the elderly and those with weakened immune systems, the infection can be serious and sometimes fatal. Listeria infection can also cause miscarriages and stillbirths in pregnant women.
The Hill
32 minutes ago
- The Hill
FDA may pull authorization for Pfizer COVID shot for kids under 5
The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer's COVID-19 vaccine for healthy children under 5 years old, the company confirmed Wednesday. The move would add another barrier for parents who want to vaccinate healthy children, as shots from Moderna and Novavax were approved for more limited populations. In May, Health and Human Services Secretary Robert F. Kennedy Jr. said that the Centers for Disease Control and Prevention (CDC) would no longer recommend COVID-19 vaccines for healthy children or pregnant women. The CDC then updated its immunization schedule to reflect that children with no underlying health condition 'may receive' COVID-19 vaccines after consulting with a health care provider — what's known as 'shared decision-making.' If FDA pulls its emergency use authorization, Pfizer's vaccine would no longer be available to any children younger than 5. Right now, Moderna and Novavax shots could be administered 'off label' to healthy children. 'We are currently in discussions with the agency on potential paths forward and have requested that the EUA for this age group remain in place for the 2025-2026 season,' a Pfizer spokesman told The Hill. 'It is important to note that these deliberations are not related to the safety and efficacy of the vaccine which continues to demonstrate a favorable profile,' the company added. The Guardian first reported on the FDA's potential move. In a statement to The Hill, HHS said it wouldn't comment on potential changes. 'The COVID-19 pandemic ended with the expiration of the federal public health emergency in May 2023. We do not comment on potential, future regulatory changes. Unless officially announced by HHS, discussion about future agency action should be regarded as pure speculation,' HHS spokesman Andrew Nixon said. Pfizer has had full FDA approval for its COVID-19 vaccine for individuals age 12 and older since 2022.
